Property:Results during intervention
This is a property of type Text.
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
NA +
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Time of onset of symptoms (graph only): p = 0.66 +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
NA +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
NA +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
Intervention arm: mean levels of 25(OH)D increased significantly from 21 to 39 ng/mL (p=0.0001),
placebo arm: no significant change (p=0.14) +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Nausea (all three cycles): no significant difference for mean nausea in ginger vs. placebo arm
Subgroup analysis for different chemotherapies: no significant arm differences +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
NA +
No statistically significant difference;
median overall survival in the intervention arm was 39 months and 40 months in control arm +
No statistically significant difference in mortality between the two groups during the 46-months follow up;
median progression-free survival for both arms: 10.5 months +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
In week 2, 4 and 6 no statistically significant differences in mucositis intensity between arms;
in the 8th, 12th, 16th, and 20th week of chemotherapy there were statistically significant differences between both arms (p < 0.005)
No statistically significant difference in the mucositis treatment period between both arms
Increased drug effect with decreased mucositis intensity over increased time in the intervention arm (p < 0.005). +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
During 2nd week no statistically significant differences in the arms;
during 4th week the intensity of xerostomia in the drug arm was less than the placebo arm (p < 0.005), a trend which continued until the 16th week of treatment;
during 18th week no differences;
during 20th week significantly lower in the intervention arm (p < 0.005)
No significant differences in terms of xerostomia treatment
Increased drug effect with decreased xerostomia intensity over increased time in the intervention arm (p < 0.005). +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
No statistically significant differences between the arms +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
From the 6th week until the 20th week less pain intensity in the intervention arm than in the placebo arm (p < 0.005)
Increased drug effect with decreased degree of pain over increased time in the intervention arm (p < 0.005) +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
NA +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
NA +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
NA +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
NA +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
''Daywise comparison''
No significant arm difference at all time points:
Day 1: p=0.08
Day 2: p=0.29
Day 3: p=0.17
Day 4: p= 0.16
Day 5: p=0.42
''Mean after intervention''
No significant difference in number of retching episodes, p=0.141 +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
''Daywise comparison''
At T2 (day2), T3 (day 3) and T5 (day 5) intervention arm significantly less frequent vomiting than control arm, Number of vomiting episodes mean (SD) for intervention vs. control:
T2 (day 2): 0 (0.1) vs. 0.3 (0.6), p=0.01
T3 (day 3): 0 (0.1) vs. 0.2 (0.4), p=0.01
T5 (day 5): 0 (0) vs. 0.2 (0.4), p=0.04; no significant difference for T1 (day 1) or T4 (day 4) (p=0.21 and 0.07)
''Mean after intervention''
Intervention arm significantly less frequent vomiting than control arm, number of vomiting episodes mean (SD) for intervention vs. control: 0 (0) vs. 0.2 (0.3), p=0.011 +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
''Daywise comparison''
At T2 (day2)-T5 (day 5) intervention arm significantly less nausea than control arm, VAS mean (SD) for intervention vs. control:
T2 (day 2): 3.8 (1.9) vs. 6.3 (1.9), p<0.001
T3 (day 3): 3.8 (1.8) vs. 6.5 (1.8), p=0.001
T4 (day 4): 3.7 (1.9) vs. 6.3 (1.8), p=0.001
T5 (day 5): 2.8 (1.7) vs. 5.4 (2.3), p=0.001; no significant difference for T1 (day 1) (p=0.15)
''Mean after intervention''
Intervention arm significantly less nausea than control arm, VAS mean (SD) for intervention vs. control: 3 (1.5) vs. 5.1 (1.5), p<0.001 +